Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Sangamo Therapeutics partners with Genentech for genomic medicines development
Dec 15, 2024•over 1 year ago
Contract Type
partnership
BrisbaneBiotechnologyHealth CareGeneticsTherapeuticsDescription
Sangamo Therapeutics has entered a global license agreement with Genentech to develop genomic medicines for neurodegenerative diseases, which focuses on the tau gene related to Alzheimer's disease and other tauopathies. This partnership includes a $50 million upfront payment and potential milestone payments of up to $1.9 billion, extending Sangamo's financial runway into the first quarter of 2025.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months
Sangamo Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.